The GLP-1 receptor agonist efficacy ladder keeps climbing: semaglutide (~15% mean weight loss), the dual GIP/GLP-1 agonist tirzepatide (~21%), and triple agonists such as retatrutide (glucagon/GIP/GLP-1) reporting even greater reductions in Phase 2. The 2026 pipeline is crowded with next-generation candidates aiming for greater efficacy, oral delivery, and muscle preservation.